16.00
-0.93%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Welgene Biotech Co
Its shares trade on Taipei Exchange under the ticker 6661.TWO. It has been listed since 23 October 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 375.9m and net income of TWD 1.3m. At that date it held total assets of TWD 622.2m and shareholders' equity of TWD 281.3m.
Welgene Biotech Co., Ltd. engages in the provision of biotechnology services including genetic testing, molecular diagnosis, and bioinformatics support for universities, hospitals, pharmaceutical companies, and others. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-10-23. The firm focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The firm is also engaged in the trading of medical equipment. The firm mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The firm mainly operates in Taiwan market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 23 Oct 2017
- Website
- welgene.com.tw ↗
Leadership
Pay as last reported
- Mr. Guihong ChenChairman of the Board, since 2022
- Ms. Ying Jen ChenDeputy General Manager-Management Division, Manager of Finance & Accounting, Director, since 2014
- Ms. Yixing LinGeneral Manager, Director, since 2004
- Mr. Yanliang LiDeputy General Manager
- Yijing GuoDirector
- Jiaqi LinDirector
- Yanling LiIndependent Director
- Zhaoyuan WuIndependent Director
- Yuncheng YangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Welgene Biotech Co Ltd focuses on DNA microarray and Next Generation Sequencing technologies in Taiwan.
- The company provides genetic testing services to universities, hospitals, and pharmaceutical companies in Taiwan.
- Welgene Biotech Co Ltd operates two business segments: Biotechnology Testing and Equipment Trading in Taiwan.
Weaknesses
- The company's operations are limited to the Taiwan market with no international expansion mentioned.
- Welgene Biotech Co Ltd has no presence in other countries or regions beyond Taiwan.
- The firm's business segments are restricted to Biotechnology Testing and Equipment Trading in Taiwan.
Opportunities
- Welgene Biotech Co Ltd can expand its DNA microarray services to new healthcare facilities in Taiwan.
- The company may grow its molecular diagnosis offerings within Taiwan's hospital network.
- Welgene Biotech Co Ltd could increase its bioinformatics support for pharmaceutical companies in Taiwan.
Threats
- The company faces competition from other biotech firms in Taiwan's limited market.
- Welgene Biotech Co Ltd operates in a highly regulated health care sector in Taiwan.
- The firm's reliance on Taiwan's domestic market poses a risk if local demand declines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.